Converting enzyme inhibitor or AT1-receptor blocker for decreasing long-term mortality in patients with stroke history and renal dysfunction? [7] (multiple letters)

Fournier A.Godefroy O.Oprisiu R.Slama M.Andrejak M.MacWalter R.S.Wong K.Y.K.2024-08-042024-08-0420030039-2499https://doi.org/10.1161/01.STR.0000044950.15362.A4https://hdl.handle.net/11616/90470[No abstract available]eninfo:eu-repo/semantics/openAccessangiotensin 1 receptor antagonistatenololcaptoprildipeptidyl carboxypeptidase inhibitorindapamidelosartanperindoprilthiazide diuretic agentanamnesiscell protectionclinical trialcomorbiditydisease associationdisease coursedrug efficacyhumankidney diseasekidney functionlettermortalitypriority journalrecurrent diseaserisk assessmentstrokesudden deathtreatment outcometreatment planningAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCerebrovascular AccidentClinical TrialsHumansIndapamideKidney DiseasesPerindoprilRamiprilReceptor, Angiotensin, Type 1Receptors, AngiotensinConverting enzyme inhibitor or AT1-receptor blocker for decreasing long-term mortality in patients with stroke history and renal dysfunction? [7] (multiple letters)Letter341891251174210.1161/01.STR.0000044950.15362.A42-s2.0-0037226842Q1